Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v19-EN Version v5-EN
Language English English
Date Updated 2022-10-07 2022-01-27
Drug Identification Number 02230019 02230019
Brand name VIOKACE VIOKACE
Common or Proper name Pancrelipase Pancrelipase
Company Name NESTLE ENTERPRISES S.A. NESTLE ENTERPRISES S.A.
Ingredients AMYLASE LIPASE PROTEASE AMYLASE LIPASE PROTEASE
Strength(s) 56400UNIT 10440UNIT 57100UNIT 56400UNIT 10440UNIT 57100UNIT
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL ORAL ORAL
Packaging size 100 tablet bottles 100 tablet bottles
ATC code A09AA A09AA
ATC description DIGESTIVES, INCL ENZYMES DIGESTIVES, INCL ENZYMES
Reason for shortage Shortage of an active ingredient. Shortage of an active ingredient.
Anticipated start date 2022-08-01 2022-06-01
Actual start date 2022-09-01
Estimated end date Unknown
Actual end date 2022-10-06
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments We are pleased to tell you that Viokace 10440 and Viokace 20880 stock is now available for sale. Please place your orders as you normally would (either through EDI order by contacting Customer Service at): orders@apcipharma.com. Thank you for your patience. There is an anticipated shortage of Viokace 10,440 tablets estimated for June 2022. Updates to the status will be made as available.
Health Canada comments